OPTHHealthcare · Drug Manufacturers - Specialty & Generic

OPTH Stock Forecast: Optimi Health Corp. Price Predictions for 2026-2027

Last close, 12 Oct 2026

$3.63

−9.70% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 9 Oct 2026 — in the weakest quartile.

Market cap

$17.4M

Ticker Nerd rank

9/ 100

Median analyst target

—

Analysts covering

—

Revenue$140K−28.6% y/y

Operating income−$2.1M

Net income−$2.4M

Free cash flow−$2.9M

Quarterly, 6 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−15.6%

−17.9%

From high

−40.3%

From low

0.0%

$3.63

$6.08

Range since 20 May 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

OPTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Optimi Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 9 Oct 2026

9/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Volatility

Revisions

Momentum

Value

Accruals

Growth

Quality

Issuance

Size (87): Smaller than most of the companies we track.

Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OPTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OPTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 20 May 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

OPTH appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

OPTH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

OPTH vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OPTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Optimi Health Corp. (OPTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −2.4×
Price / sales: 92.7×
Price / book: 1.3×
EV / EBITDA: −2.3×

Growth & margins

Revenue growth (YoY): −28.6%
Earnings growth (YoY): −28.6%
Gross margin: 47.5%
Operating margin: −957.8%
Net margin: −16.0%

Returns & dividend

Return on equity: −54.4%
Return on assets: −16.1%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Optimi Health Corp. (OPTH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Optimi Health Corp. has a market value of $17.4M and an enterprise value of $6.8M.
Revenue in the twelve months to 30 June 2026: $176K. The latest quarter shrank 28.6% year on year.
Net income over the same four quarters: −$6.9M, a −3927.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$5.3M, after $110K of capital spending.
Shares outstanding: 5.7M.
Trailing P/E: −2.4×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Optimi Health Corp. employs 6 people — $29K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

OPTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
OPTHOptimi Health Corp.	$17.4M	9
SHPHShuttle Pharmaceuticals Holdings, Inc.	$25.0M	18
AYTUAytu Biopharma, Inc.	$21.1M	90
CPHIChina Pharma Holdings, Inc.	$26.7M	41
TXMDTherapeuticsMD, Inc.	$20.7M	79
RMTIRockwell Medical, Inc.	$28.9M	56
IXHLIncannex Healthcare, Inc.	$32.4M	24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Optimi Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OPTH news & analysis

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

GlobeNewsWire · 26 Oct 2026positive

Optimi Health established Optimi Australia Pty Ltd, a wholly owned subsidiary responsible for distribution and business development in Australia, and appointed Adrian Jones as Director of Australian Operations. The subsidiary will manage sales, distribution, and prescriber relationships in the country.

Why it matters — The announcement sets out Optimi’s dedicated structure and leadership for its Australian sales and distribution activities.

Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia

GlobeNewsWire · 20 Oct 2026positive

Optimi Health completed a production batch of MDMA capsules at its GMP facility in British Columbia. The batch is expected to supply a proposed Canadian Phase 3 PTSD trial, a MAPS-partnered clinical trial in Israel, and a planned commercial export to Australia before the end of 2026.

Why it matters — The batch is intended to support three clinical or commercial programs, including a proposed Canadian trial involving up to 100 veterans and frontline workers.

Optimi Health to Present at the ThinkEquity Conference

GlobeNewsWire · 7 Oct 2026neutral

Optimi Health announced it will participate in the ThinkEquity Conference on October 15, 2026, at the Mandarin Oriental Hotel in New York City. Management will present a corporate overview at 4:00 p.m. Eastern time and be available for one-on-one meetings with registered investors.

Why it matters — OPTH watchers may note the scheduled corporate presentation and investor meetings as an opportunity to hear from management.

Optimi Health Appoints Melanie Pump to Board of Directors

GlobeNewsWire · 29 Sept 2026positive

Optimi Health Corp. has appointed Melanie Pump to its board of directors. Pump brings over 25 years of leadership experience spanning technology, digital infrastructure, software, fintech, and emerging growth companies.

Why it matters — A seasoned finance executive joining the board adds experienced leadership to Optimi Health's governance as the company continues to develop its operations.

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

GlobeNewsWire · 23 Sept 2026positive

Optimi Health Corp. announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured end to end at its cGMP facility in Princeton, British Columbia under a Health Canada Drug Establishment Licence. The batch supports a Health Canada-approved Phase 2 MDD trial and commercial supply for treatment-resistant depression.

Why it matters — The completed production and quality release confirms Optimi's operational manufacturing capability under its Health Canada licence, advancing its supply commitments for both a Phase 2 depression trial and commercial TRD product.

FAQ

Frequently asked questions about OPTH stock

How does Ticker Nerd's model rank OPTH?

As at 9 Oct 2026, Optimi Health Corp. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

What is the OPTH stock forecast for 2030?

No analyst covering Optimi Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPTH are extrapolating price history, which says nothing about the business.

What does Optimi Health Corp. do?

Optimi Health Corp. is a Canadian pharmaceutical and nutraceutical manufacturer focused on controlled psychedelic drug products and functional mushrooms.

What is the latest news on OPTH?

The most recent item we track (GlobeNewsWire, 26 Oct 2026): "Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity". Optimi Health established Optimi Australia Pty Ltd, a wholly owned subsidiary responsible for distribution and business development in Australia, and appointed Adrian Jones as Director of Australian Operations. The subsidiary will manage sales, distribution, and prescriber relationships in the country.

Company

About Optimi Health Corp.

Optimi Health Corp. is a Canadian pharmaceutical and nutraceutical manufacturer focused on controlled psychedelic drug products and functional mushrooms. The company produces finished-dose MDMA and psilocybin products, along with related ingredients and formulations used in regulated clinical and therapeutic programs. Its current business includes farming, processing, extraction, manufacturing, testing, and distribution of mushroom biomass, mushroom extracts, and supplements, serving authorized clinics, pharmacies, clinical trials, and health and wellness partners. Optimi Health Corp. also supplies botanical and pharmaceutical-grade psychedelic compounds for markets that require compliant, standardized production and traceability. Headquartered in Princeton, British Columbia, and incorporated in 2020, the company plays a specialized role in the emerging regulated market for psychedelic medicines and mushroom-based wellness products.

CEO Mr. Dane Stevens · 6 employees · Canada · https://www.optimihealth.ca